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The switch from latency to lytic phase of Epstein–Barr virus (EBV) is coordinated by the expression of two viral transactivators known as
ZEBRA and RTA. The BFRF1 gene has been shown to be transcribed during the early phases of EBV lytic cycle. Here, we characterized the
BFRF1 promoter showing that ZEBRA transfection stimulated BFRF1 expression, whereas RTA induced BFRF1 only after the transfection of an
amount of plasmid largely in excess than that sufficient to stimulate the expression of other RTA-responsive genes. However, a co-operative effect
between ZEBRA and RTA in the expression of BFRF1 is evident since the transfection of RTA can rescue the transactivating capacity of a mutant
of the ZEBRA protein, known as Z(S186A), that has a substitution affecting the DNA binding region. Moreover, we identified one ZEBRA-
responsive element (ZRE) and one RTA-responsive element (RRE) within the BFRF1 promoter region.
D 2005 Elsevier Inc. All rights reserved.Keywords: Epstein–Barr virus; BFRF1 regulation; Lytic cycleIntroduction
Epstein–Barr virus (EBV), a highly diffused gamma-
herpesvirus, is the etiologic agent of the infectious mononu-
cleosis and has been associated to different malignancies of B
lymphoid and epithelial origin such as Burkitt’s lymphoma
(BL), Hodgkin’s disease, B and T cell lymphomas in
immunocompromised individuals and nasopharyngeal carcino-
ma (Kieff and Rickinson, 2001). After primary contact, EBV
establishes a life long infection, and the virus can be found in
circulating B lymphocytes as well as in epithelial cells of the
nasopharynx and the tongue. During this period, the viral
infection is mainly kept in a latent state, characterized by the
expression of a restricted subset of viral proteins. Under
circumstances largely unknown, the EBV replicative cycle is
reactivated, thus leading to a new viral progeny, which causes
phases of viremia and viral shedding in the saliva.
Most of the knowledge on EBV biology is derived from
B lymphoblastoid cell lines immortalized by the virus. In
these cells, EBV establishes a latent infection, and the lytic0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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different stimuli. Two EBV proteins, translated from the
BZLF1 and BRLF1 genes and indicated as ZEBRA and
RTA respectively, have been shown to be the key regulators
of the lytic cycle (Countryman and Miller, 1985; Zalani et
al., 1997; Ragoczy et al., 1998, Feederle et al., 2000). These
proteins act as transactivators by inducing directly or
indirectly the expression of the lytic genes. About 30 EBV
lytic proteins have been identified so far. They have been
classified in early or late lytic proteins according to the
susceptibility to be expressed in the presence of inhibitors of
the EBV DNA polymerase: lytic genes whose expression is
blocked by this treatment are classified as late genes,
whereas early lytic genes are not affected (Serio et al.,
1997). Alternatively, lytic genes have been distinguished in
three groups according to their responsiveness to the two
viral transactivators: a class directly activated by ZEBRA, a
second class regulated by RTA and a third group whose
expression is synergistically induced by ZEBRA + RTA
(Ragoczy et al., 1998).
We have identified a novel EBV gene, BFRF1, that encodes
a lytic protein of 37 kDa expressed in the early phases of the
replicative cycle (Farina et al., 2000). The BFRF1 gene and6) 109 – 116
www.e
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encompasses this gene are strongly conserved among herpes-
viruses, thus suggesting that proteins encoded within this
fragment play a role in biological functions that are pivotal to
herpesviruses replication (Hudson et al., 1985). Indeed, it has
been recently shown that the proteins generated by the viral
genes BFRF1 and BFLF2 are co-operatively involved in the
process of egress of the newly synthesized virions from the
nuclei of infected cells (Lake and Hutt-Fletcher, 2004; Farina et
al., 2005; Gonnella et al., 2005).
In the present study, we have studied the mechanisms of
regulation of the BFRF1 gene in an attempt to add a further
element to the knowledge of the EBV replicative program.
Results and discussion
Characterization of the 5V-end of the BFRF1 transcript
We initially mapped the start site of the BFRF1 mRNA by
5V-RACE using RNA isolated from the EBV-positive Raji cell
line chemically induced to lytic cycle by treatment with TPA
and butyrate. A reverse transcription reaction was performed
on extracted RNA, and amplified cDNAs were purified and
cloned to be fully sequenced.
The sequence of the longest 5V-clone generated showed that
the transcription started at position 58,585 of the EBV B95-
8 DNA sequence, at 306 bp from the BFRF1 ATG (genomic
co-ordinates 58,891) and is reported in Fig. 1A. The sequence
TTAATA located at position 58,563 (22 bp from theFig. 1. (A) Sequence of the promoter region of the BFRF1 gene and mapping of the t
(bent arrow) and the position of the primers used for the 5V-RACE (leftward arrow
underlined. All the positions are calculated relative to the BFRF1 ATG (bold charac
and RTA-responsive elements (ZIIIA and RRE-F1, respectively) and the negative ridentified transcription start) is likely to represent the TATA
box of the BFRF1 gene.
Subsequently, studies were undertaken to evaluate the
mechanisms that regulate the expression of the BFRF1 gene.
We have previously observed that high levels of BFRF1
expression in EBV-infected cell lines are obtained after the
combined treatment with TPA and butyrate. TPA-mediated
activation of the EBV lytic cycle is known to be based on the
capacity to drive the expression of the viral transactivator
BZLF1. This is achieved through the activation of a complex of
factors that by binding to specific DNA sequences known as
TPA Responsive Elements (TREs) in the promoter region of
responsive genes finally activate the transcription machinery
(Flemington and Speck, 1990; Liu et al., 1997). In the case of
EBV, the ZEBRA protein is subsequently phosphorylated and
acts as BRLF1 transactivator, thus leading to the co-operative
induction of the viral replicative cycle (Baumann et al., 1998;
Feederle et al., 2000; El-Guindy and Miller, 2004).
On the basis of the mapping of BFRF1 transcription start,
we performed a computer analysis of the region upstream the
BFRF1 ATG, searching for known TPA (TRE)-, ZEBRA
(ZRE)- or RTA (RRE)-responsive consensus motifs, and the
results are summarized in Fig. 1B. No TRE is present in the
BFRF1 promoter region, whereas a canonical ZRE and one
putative RRE, similar to the RRE-DR1 elsewhere described
(Gruffat and Sergeant, 1994), are present at positions 58,373
and 58,518 of the B95-8 EBV strain, with respect to the
translation start located at 58,891. In detail, a ZIIIA motif
(TGAGCCA) at 373 bp from the ATG and a putative RREranscription start site of BFRF1 determined by 5V-RACE. The transcription start
s) are indicated. The positions of the potential RRE, ZRE and TATA box are
ters). (B) Schematic diagram indicating the positions of the potential ZEBRA-
egulator consensus sequence (ZV) relative to the BFRF1 ATG.
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positioned at 518 bp, were found by the computer analysis
(Fig. 1B). The RRE-F1 motif is not a canonical RRE since the
consensus sequence usually found is GNCCN9GGNG, how-
ever, it is similar in the 3V-core to an RRE present within the
EBV BHLF1 promoter (indicated as BHLF1-I) recently
described by other authors, which has been shown to be very
active in responding to RTA expression (Chen et al., 2005).
In EBV-infected cell lines, BFRF1 activation is mainly
regulated by ZEBRA expression
In EBV-infected cell lines, the switch from latency to
replication is driven by either ZEBRA or RTA. In epithelial as
well as in some permissive B lymphoblastoid cell lines, the
transfection of either ZEBRA or RTA genes triggers the
expression of the other immediate-early factor, and, together,
these proteins act individually or in synergy on downstream
targets to activate the viral lytic cascade (Ragoczy et al., 1998).
In other B cell lines, such as Raji cells, RTA transfection is not
sufficient to stimulate the full viral cascade, and only a subset
of early proteins are expressed.
We set up transfection experiments on Raji cells to
determine the responsiveness of the BFRF1 gene to the
exogenous expression of either ZEBRA and/or RTA. We also
took advantage of a plasmid expressing a mutant form of theFig. 2. Expression of EBV lytic proteins in transfected Raji cell. (A) Western blot an
after transfection of either pCMVgenZ, pRTS/RTA alone or in combination and pCM
Raji cells; lane 2: transfected with 10 Ag of pCMVgenZ; lane 3: transfected with 1 Ag
RTA; lane 5: 10 Ag of pCMVgenZ(S186A); lane 6: transfected with 10 Ag of pCMVg
transfection and assayed by monoclonal antibodies. Equal loading was assessed b
showing that increased amounts of exogenous RTA induce a weak BFRF1 expressio
lane 3: transfected with 10 Ag of pRTS/RTA. Cell extracts collection and equal loaZEBRA protein, known as Z(S186A): this mutant has a
substitution of the serine located at position 186, which is
phosphorylated in TPA-treated cells, with an alanine residue
(Francis et al., 1997; El-Guindy et al., 2002). More important,
it has been observed that the Z(S186A) mutant has lost the
ability to induce the lytic cycle, although still maintaining the
capacity to co-operate with RTA and transactivate specific
promoters (Francis et al., 1999; Bhende et al., 2005).
Raji cells were electroporated with plasmid expressing
either RTA, ZEBRA or Z(S186A), and protein extracts were
analyzed by Western blot to detect the expression of four viral
lytic gene products: ZEBRA, RTA, BFRF1 and EA-D, the
BMFR1-encoded protein.
As shown in Fig. 2A, all the four lytic proteins were easily
detected following ZEBRA transfection as well as in co-
transfection with RTA. On the other hand, RTA was able to
induce EA-D expression but not BFRF1 and BZLF1, as also
observed in the same cell line by other authors (Ragoczy and
Miller, 1999). Furthermore, the Z(S186A) mutant failed to
induce both EA-D and BFRF1. However, BFRF1 and EA-D
expressions were strongly detected when RTA was co-
transfected with Z(S186A). Interestingly, as also observed by
other authors, the transactivating capacity of RTA is affected by
the amount of the plasmid transfected. Indeed, increasing
amounts of RTA (5 and 10 Ag, respectively) caused a higher
level of EA-D expression and the detection of a signal ofalysis showing the expression of BRLF1, BMRF1, BFRF1 and BZLF1 proteins
VgenZ(S186A) alone or in combination with pRTS/RTA. Lane 1: untransfected
of pRTS/RTA; lane 4: transfected with 10 Ag of pCMVgenZ and 1 Ag of pRTS/
enZ(S186A) and 1 Ag of pRTS/RTA. Cell lysates were collected after 48 h after
y probing the blot with monoclonal antibodies to h-Actin. (B) Western blots
n. Lane 1: untransfected Raji cells; lane 2: transfected with 5 Ag of pRTS/RTA;
ding as described in (A).
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is sufficient to induce EA-D transactivation (Fig. 2B).
However, we tend to consider that usage of high amounts of
exogenous proteins could influence the molecular stoichiom-
etry, thus rendering the effects less stringent with the
physiological conditions. Overall, these data seem to indicate
that, in EBV-positive B cell lines, BFRF1 expression is mainly
responsive to ZEBRA, but a role is certainly played also by
RTA given the capacity to rescue the BFRF1 transactivation of
the ZEBRA mutant Z(S186A).
Identification of two consensus sequences responsive to
ZEBRA and RTA within the BFRF1 promoter
The presence of two potential ZEBRA- and RTA-respon-
sive elements in the 5V-region of the BFRF1 promoter and the
results of the previous set of experiments led us to analyze in
detail the role played by the consensus sequences highlighted
by the computer analysis. Therefore, we set up experiments of
luc-assay using different subfragments of the 5V-region ofFig. 3. Schematic diagram of the constructs used in luc-assays to characterize the BFR
ZIIIA motifs in the constructs 679pF1, 429pF1 and 275pF1. (B) Sequence mut
RRE-F1 consensus motifs. +1 indicates the BFRF1 ATG. The mutated bases within
underscored.BFRF1 gene: the 679pF1 and 429pF1 that contain the
wild type sequence of the EBV genome and encompassing
both the RRE-F1 and ZIIIA or only the ZIIIA motifs,
respectively. We also assayed the constructs 679pF1-
ZIIIA(c,a) and 429pF1-ZIIIA(c,a) containing a mutated
ZIIIA domain as well as the 679pF1RRED mutant with
deletions in the consensus sequence of the RRE-F1 domain.
Finally, we generated a subfragment indicated as 275pF1,
which does not contain neither the RRE-F1 nor the ZIIIA
motifs (Figs. 3A and B).
The constructs so generated were transfected in an EBV-
negative epithelial cell line, known as 293 cells, in the presence
of either ZEBRA or RTA expressing plasmids; the luciferase
activity was assayed 48 h post-transfection. As described in
Fig. 4A, RTA was able to drive the transactivation of the
679pF1 promoter more efficiently than ZEBRA alone,
however, only a slight increase rather than a synergistic effect
was observed when both RTA and ZEBRAwere co-transfected.
In 429pF1, ZEBRA-induced transactivation was higher
(13.3), whereas activation by RTA was significantly reducedF1 promoter. (A) Map showing the presence or absence of the ZV, RRE-F1 and
ations in the plasmids used for the luciferase assays to inactivate the ZIIIA or the
the ZIIIA motif are underlined. The bases deleted to inactivate the RRE-F1 are
Fig. 4. Analysis of the BFRF1 promoter region. EBV-negative 293 cells were co-transfected with reporter plasmids and pCMVgenZ, pRTS/RTA Bars represent the
mean of three experiments. Error bars show the standard deviation. Folds of activation are calculated relative to the transfection of control vector. As experimental
controls, the promoterless reporter plasmid pGL3Basic and the Zp3Luc, bearing the BZLF1 promoter responsive to ZEBRA, were used. (A) 293 cells were
transfected with 0.5 Ag of 679pF1, 429pF1 or 275pF1 in the presence of 0.5 Ag of pCMVgenZ or 0.2 Ag pRTS/RTA alone or in combination. Fold of activation
of each transfection experiment is indicated under the graphic. The boxes highlight the higher fold of activations observed. (B) 293 cells were transiently transfected
with 0.5 Ag of 679pF1, 429pF1 (wild type); 679pF1 ZIIIA (c, a), 429pF1 ZIIIA (c, a) (containing a mutation in ZRE element); 679pF1 RRED (containing a
deletion of RRE-F1-responsive element); 679pF1MV mutant (containing a point mutation of ZV site). The reporter plasmids were co-transfected in combination
with 0.5 Ag of pCMVgenZ. (C) Transfections were performed using 0.5 Ag of 679pF1 and 679pF1 RRED. In the same experiments, the reporter plasmids were
co-transfected with 0.2 Ag pRTS/RTA.
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due to the lack of the RRE-F1 motif. Also, in this case, no
synergistic transactivation was detected when both RTA and
ZEBRAwere co-transfected. Finally, no significant stimulation
by either ZEBRA or RTA was observed in the 275pF1
reporter plasmid. This set of experiments suggested that the
RRE-F1 and ZIIIA elements present in the analysis of BFRF1
promoter region are likely to be involved in the regulation of
BFRF1 expression, although a more precise analysis was
required to confirm this finding. The absence of a real
synergistic effect by ZEBRA and RTA in stimulating the
activity of the reporter plasmids here used was ratherunexpected. A potential explanation might be the relative
weakness of the BFRF1 promoter-derived constructs to be
induced, as observed in all the series of experiments: in this
case, it is possible that the mono transfections of RTA and
ZEBRA were able to stimulate the 679pF1 and 429pF1
reporter plasmids, respectively, near to the plateau level which
can be achieved by the BFRF1 promoter. Transfection of
reduced amounts of pCMVgenZ and pRTS/RTA in the
presence of the above mentioned reporter plasmids failed in
inducing significant transactivation, thus preventing us from
analyzing a potential synergism by lowering the scale of the
response.
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of the ZIIIA and RRE-F1 motifs to act as responsive elements
for ZEBRA and RTA. As shown in Fig. 4B, ZEBRA induces
the activation of the control plasmid bearing the BZLF1
promoter, already known to be responsive (22) and is also an
efficient transactivator of the 429pF1 plasmid (15.8). The
mutation of the ZIIIA site within this construct heavily affected
the transactivation capacity of ZEBRA, reducing by more than
5-fold compared to the 429pF1 (3 of activation above
background). Furthermore, the transactivation by ZEBRA was
not so high when we used the 679pF1 construct, which
retains the ZIIIA and the RRE elements (6.2 activation). The
mutagenesis of the ZIIIA consensus motif reduced the
ZEBRA-mediated transactivation of the construct, whereas
the mutation of the RRE-F1 was almost ineffective (3.7 and
5.6 respectively), compared to the wild type 679pF1.
The finding of the low transactivation of the plasmid
bearing the longer form of the promoter region led us to
hypothesize the existence in the region between 429 and
679 of a repressor element that might interfere with the
ZEBRA-mediated induction. The search for known repressor
motifs by computer analysis indicated the presence in the 679
fragment of a sequence called ZV (5V-CAGGTG-3V) also
identified in the promoter of BZLF1 gene (Fig. 1B) (Kraus et
al., 2001). This site is recognized by a factor indicated as ZEB
(Kraus et al., 2003). To assess the role of this sequence in the
activation of 679pF1 reporter plasmid by ZEBRA, we
introduced the same single base substitution (5V-CAGGTc-3V)
in the ZV site described in the abovementioned report. Thus,
the 679pF1MV mutant was generated, and we observed that
the luciferase activity of this reporter in the presence of
ZEBRA was increased (10) when compared to that of the
wild type 679pF1 construct (6.2) as shown in Fig. 3A,
although the mutation in the putative ZV site was not sufficient
to restore the same level of transactivation observed in the
429pF1 plasmid. It should be noticed however that the
relative position of the ZV domain in the BFRF1 promoter is
upstream with respect to the ZIIIA element, whereas for
example in BZLF1 promoter, its position is downstream than
that of the known ZIIIA/ZIIIB and ZII sites that bind activators
(Kraus et al., 2001). It is possible that the relative position of
these elements might affect the repressor function of the ZV
motif.
In the same set of experiments, we also assayed the capacity
of RTA to transactivate the 679pF1 plasmid, which bears the
RRE-F1 domain. As shown in Fig. 3C, RTA transactivates the
reporter plasmid (14.8 over background), whereas the
deletion of the RRE-F1 region lowered by 6-fold the
responsiveness of the assay (2.5). The capacity of RTA to
induce the 679pF1 plasmid is as good as that observed for
ZEBRA to transactivate the 429pF1 construct, although in
Raji cells RTA alone failed to induce BFRF1 induction, unless
we transfected high amount of pRTS/RTA plasmid. Some
hypotheses could explain this discrepancy: epigenetic factors
could influence the responsiveness of the BFRF1 promoter to
ZEBRA and RTA in the context of the whole EBV genome.
Alternatively, motifs located 5V- or 3V-promoter fragmentscloned in the 429pF1 and 679pF1 constructs might be
capable to influence the response to the two viral transactiva-
tors in vivo.
It should be noticed that all the luc-assays were also
conducted in the EBV-negative B cell line, DG75, confirm-
ing the results observed in the epithelial cells. Taken
together, the results of the assays indicate that in the context
of a reporter plasmid the canonical ZIIIA and the novel
RRE-F1 elements identified by the computer analysis
represent the motifs that provide the responsiveness to
ZEBRA and RTA, respectively.
In conclusion, we have characterized the transcription start
of the BFRF1 mRNA by 5V-RACE. The results here described
indicated that BFRF1, encoding a protein which is part of the
early phase of the replicative cycle, can be classified as a
gene directly transactivated by ZEBRA and RTA, the
immediate-early proteins of EBV, with the former being more
effective in stimulating BFRF1 expression in EBV-infected
cells. Furthermore, the observation that RTA can rescue the
capacity of Z(S186A) in transactivating BFRF1 adds a new
tool for studies aimed to better define the mechanisms that
lead to the EBV replicative cycle. In previous reports, a new
classification of EBV lytic genes based on the responsiveness
to RTA or ZEBRA alone or in combination has been
proposed (Ragoczy and Miller, 1999): the results of the
present assays indicate that BFRF1 gene can be included in
this latter group.
Materials and methods
Cell lines
DG75 is an EBV-negative human B-cell line derived from a
BL (Ben-Bassat et al., 1977). Raji is a human B cell line
derived from a BL containing an EBV strain defective in viral
replication (Decaussin et al., 1995). 293 is a human embryonic
epithelial kidney cell line (Graham et al., 1977). All cell lines
were grown in RPMI 1640 medium supplemented with 10%
fetal calf serum. EBV chemical induction on Raji cells was
achieved by treatment for 48 h with either 12-O-tetradeca-
noylphorbol-13-acetate (TPA) 20 ng ml1 and 3 mM of sodium
butyrate.
5V-RACE
To study the transcription start site of BFRF1 gene, 5V-
RACE was performed with RNA isolated from Raji cell line
induced by TPA/butyrate treatment. Total RNA was extracted
with TRIzol (Life Technologies). Reverse transcription and
PCR were carried out using the 5V-RACE kit (Roche) in the
presence or absence of reverse transcriptase as control. For the
reverse transcription, a primer designated as GP1 (CGTTATT-
GAGCTCGTCT, coordinates 58,934–58,917) was used. For
the subsequent 5V-RACE, PCR was synthesized an oligonucle-
otide indicated as GP12 (GAGATTGGGGTGGATCATAGG,
coordinates 58,691–58,670) and the Oligo dT-Anchor primer
provided by the kit. Amplified cDNAs were separated on 2%
M. Granato et al. / Virology 347 (2006) 109–116 115agarose gel, purified and subsequently cloned into the pGEM-T
Easy Vector (Promega). DNA from isolated clones was then
extracted and fully sequenced.
Plasmids construction
For luciferase assays, subfragments of the region upstream
to the ATG of BFRF1 were cloned into the backbone of the
pGL3Basic vector (Promega). 679pF1 was obtained by
cloning the 665 DrdI/BglII fragment (coordinates 58,212–
58,877) into SmaI/BglII sites of the vector. 429pF1 was
generated by cloning the 415 PvuII/BglII fragment (coordi-
nates 58,462–58,877) into SmaI site of the vector. To
generate the p275F1 plasmid, we first subcloned a 746
BstxI/BglII fragment (genomic coordinates 58,131 to 58,877)
into SmaI/BglII sites of pGL3Basic vector (Promega) and
then excited a 390 bp using NheI restriction enzyme. This
construct encompasses EBV genomic coordinates 58,616 to
58,877. To generate the Zp3Luc plasmid, the 561 bp BamHI/
NaeI fragment from the BamHI Z region was cloned into the
SmaI site of pGL3Basic vector (coordinates 103,742–
103,182). pRTS/RTA containing the BRLF1 gene, pCMVgenZ
containing the BZLF1 gene and pCMVgenZ(S186A) contain-
ing a mutant of the BZLF1 gene were kindly provided by Dr.
George Miller (Yale University). The pRL-TK (Promega) was
used as an internal control plasmid expressing Renilla luciferase
driven by the thymidine kinase promoter of herpes simplex
virus.
Site-directed mutagenesis
We performed a site-directed mutagenesis of the ZIIIA and
RRE-F1-responsive element of the BFRF1 promoter using the
Exsite PCR-Based site-directed mutagenesis kit (Stratagene).
The 429pF1 ZIIIA (c,a) and 679pF1 ZIIIA (c,a) mutant
containing the ZIIIA were generated by two PCR reactions
using the primers 1C429 (5V-TGcGCCATGACACATCT-
GGGTGG-3V) (58,518–58,541) and 1A429 (5V-TGcGaCAT-
GACACATCTGGGTGG-3V (58,518–58,541) as forward
oligos coupled to the 2C429 (5V-CAAAGTCACGAGCG-
CAAACGAGC-3V (58,517–58,494) as reverse oligo. The
deletions in the RTA binding site of BFRF1 promoter were
generated in the wild type vector 679pF1 using the kit
described previously and the following primers: 1AD679 (5V-
TCACAAAGTCCTCCATCTTTGG-3V) (58,381–58,409) as
forward oligo coupled to 2D679 (5V-CCGTGGACAATCT-
GAAAAGC-3V (58,380–58,360) and 14D666 (5V-CCG-
TAATCTGAAAAGCCAGT-3V) (58,380–58,356) as reverse
oligos. All mutants obtained were fully sequenced.
Cell transfections
107 Raji cells or DG75 cells were electroporated using a
Biorad Gene Pulser (0.26 kV and 960 AF) with appropriate
amounts of DNA. For luciferase studies, the 293 cells grown in
12 or 24 multiwell were transfected by using the Lipofectamine
2000 reagent (Invitrogen) according to the manufacturer’sinstructions. 293 cells were transiently transfected with 0.5 Ag
of luciferase constructs, 0.5 Ag pCMVgenZ and 0.2 Ag of
pRTS15/RTA.
Protein extracts and Western blots
Cells were collected by centrifugation, washed in PBS,
lysed by sonication and suspended in 3 SDS sample buffer
(Sambrook et al., 1989). For Western blot analysis, the
samples were heated at 100-C for 5 min and loaded on a
12% SDS-PAGE. After electrophoresis, the gels were
transferred onto a nitrocellulose membrane according to
standard procedures (Sambrook et al., 1989). Membranes
were first blocked 1 h at RT with blocking solution (1
PBS, 0.1% Tween-20 and 5% milk) and then incubated 1
h RT with the primary antibody, washed three times with
washing solution (1 PBS, 0.1% Tween-20) and incubated
45 min RT with anti-mouse or anti-rabbit HRP-conjugated
antibodies (SIGMA) at a dilution of 1:5000 in blocking
solution. After further washes, proteins were detected by
enhanced chemiluminescence according to manufacturer’s
instructions (Roche) and visualized on X-ray films.
Reporter gene assay
Luciferase assays were performed at 24–48 h post-
transfection. 293 cells were harvested, washed twice with
phosphate-buffered saline and suspended in 150 Al of lysis
buffer (Promega) for 15 min at room temperature. Luciferase
activities were determined using the Dual-Luciferase assay
system according to the manufacturer’s instructions (Pro-
mega). The pRL-TK (Promega) was used as an internal
control plasmid. The activity of Renilla was used to calibrate
the activity of firefly luciferase. The activity of the reporter
plasmid was calculated and shown as fold activation. All the
results of the reporter assays were based on experiments
performed at least in triplicate.
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